Gilteritinib is a novel FLT3 inhibitor approved in 2019 as a monotherapy for relapsed/refractory AML harboring FLT3 mutations including internal tandem duplication (ITD), D835Y, or D835Y somatic mutations. The gene discussed is FLT3; the disease is acute myeloid leukemia.